Navigation Links
Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
Date:6/2/2008

label study is to assess overall tumor response rate, and the study may be expanded to a total of 46 subjects following complete evaluation of data from the first 15 patients.

"Bavituximab represents a completely novel approach to treating cancer that helps mobilize the body's own immune system to attack tumors and the blood vessels supporting tumor growth and spread," said Dr. Raghunadharao Digumarti, professor of medical oncology at the Nizams Institute of Medical Sciences in Hyderabad, India, and a principal investigator of the Phase I clinical trial presented at ASCO. "We believe these encouraging study results support the upcoming Phase II safety and efficacy trials of bavituximab in breast and lung cancers that we look forward to participating in."

The open label, multi-center Phase I study was conducted in patients with refractory advanced solid tumors. The study objectives were to assess the safety and tolerability of bavituximab and to characterize its pharmacokinetic profile when used in combination with standard chemotherapy. Patients received up to eight weekly doses of bavituximab in combination with docetaxel, gemcitabine or paclitaxel plus carboplatin.

"The opportunity to share the positive results of the Phase I clinical study at ASCO provides us with a great platform to inform the broader oncology community about the potential of bavituximab and our anti-PS technology," said Steven W. King, president and CEO of Peregrine. "The promising anti-tumor activity of bavituximab in combination with chemotherapy seen in the Phase I and Phase II studies to date are encouraging, and we look forward to reporting additional results in the coming months."

Bavituximab is a monoclonal antibody that binds to the cellular membrane component PS that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. By binding t
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
2. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
3. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
4. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
5. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
6. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
9. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
10. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
11. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... FOSTER CITY, Calif. , April 20, 2015 /PRNewswire/ ... with InterpretOmics Pvt. Ltd. to provide an integrated Big ... analysis of all biomarkers collected in the context of ... the needs of precise or multi-targeted drug candidates, stratified ... efficacy and disease progression free survival. ...
(Date:4/20/2015)...  "Everybody is affected by cancer sooner or later," ... brutal. We,ve got to get away from that."  If ... a loved one or friend battling for their life ... and other treatments cause the human body. It,s almost ... and succumb to the disease. Dr. Dionne has developed ...
(Date:4/20/2015)... 20, 2015 /CNW/ - Portage Biotech Inc. ("Portage" or ... is pleased to announce that its wholly owned subsidiary, ... study that showed one of its proprietary human-derived CPP ... tissue through inhibition of NFkB signalling even if administered ... permeability of the blood brain barrier (BBB) in mice ...
(Date:4/20/2015)... , April 20, 2015   Meditope Biosciences, ... using its proprietary technology, today announced presentation of data ... the development of antibody-drug conjugates (ADCs). The data were presented ... taking place April 18-22 in Philadelphia ... these data which point to the many commercial applications ...
Breaking Biology Technology:PointCross Life Sciences and InterpretOmics partner for Clinical and Genomic Biomarker Management for Drug Development 2Is Dr. Craig Dionne the Steve Jobs of Cancer Research? 2Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 2Portage's CPP Platform Delivers a Peptide Cargo Across Blood Brain Barrier 3Meditope Biosciences Presents Data At The American Association Of Cancer Research (AACR) Annual Meeting Validating Its SnAP Technology Platform 2
... May 17, 2011 Amgen (NASDAQ: AMGN ... 3 trial (,147) demonstrating that XGEVA™ (denosumab) significantly increased ... men with castrate-resistant metastatic prostate cancer that has not ... study were presented for the first time today in ...
... DIEGO, May 17, 2011 P ... that it has submitted a Biologics Master File (BMF) to ... grade CRM197 carrier protein to support the development of conjugate ... Proteins is supplying cGMP grade CRM197 carrier protein to multiple ...
... /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc. (NYSE AMEX: ... "Company"), a developer, manufacturer and distributor of botanical ... China, today announced that the Company successfully showcased ... ("the fair") recently held in Chengdu, China. ...
Cached Biology Technology:Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 2Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 3Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 4Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 5Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 6Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 7Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 8Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer 9Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA 2Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA 3China Botanic Exhibits All-Natural Products at the 65th PHARMACHINA Fair 2China Botanic Exhibits All-Natural Products at the 65th PHARMACHINA Fair 3
(Date:3/23/2015)... , March 23, 2015  In the 2014 ... fraud case conviction losses. This figure accounts for a ... according to The Nilson Report, exceeds $11 billion globally. ... tool after a crime has occurred. Investor Mark ... polygraph expert Joe Paolella partnered to administer ...
(Date:3/20/2015)... Mar. 19, 2015 Research and Markets ( ... Geometry - Global Strategic Business Report" report to their ... Hand Geometry in US$ Thousands. The report provides separate comprehensive ... Japan , Europe , ... and Rest of World. Annual estimates and forecasts ...
(Date:3/19/2015)... 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host Laura ... to pay, and ,a really big breakthrough in mobile payment.,  ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... the worlds of law, geography, economics, public health ... College London) on Friday September 19th to examine ... locally-rooted champions for global sustainability, reaching out to ... change. The symposium, which is called: "The Sustainable ...
... no such thing as a ,safe, tan based on ultraviolet ... the October issue of Pigment Cell & Melanoma Research ... Cell Societies (IFPCS) and the Society for Melanoma Research. ... in the fields of cell biology, dermatology and epidemiology ...
... the U.S. Environmental Protection Agency (EPA) have made ... Implications of Nanotechnology (CEIN). The centers, led ... nanomaterials interact with the environment and with living ... assessment and mitigation strategies useful in the development ...
Cached Biology News:Universities develop a more sustainable future 2More than skin deep: There's no such thing as a 'safe' suntan, researchers warn 2NSF and EPA establish 2 centers for environmental implications of nanotechnology 2NSF and EPA establish 2 centers for environmental implications of nanotechnology 3NSF and EPA establish 2 centers for environmental implications of nanotechnology 4
... is the only PCR system that ensures ... time. It provides accuracy, consistency, and dependability ... the property of the DNA templates. This ... a unique blend of thermostable enzymes that ...
Special grade: for molecular biology Density: 1.000 g/mL (20 C)...
... Designed to meet the needs ... animal component-free medium supports fast ... cell densities, while maintaining high ... protein production using the Baculovirus ...
... This CLS number ... number, created to easily ... If showing no availability ... the old Sigma-Aldrich number ...
Biology Products: